Browse the evidence

A median SPAN score (52.8) was associated with a 41% lower risk of MACE (HR: 0.59; 95% CI: 0.49, 0.70).

Practitioners should aim for a balanced SPAN score to lower cardiovascular event risk.

Latina women experiencing food insecurity consumed fewer vegetables compared to those with food security (1.7 vs. 3.0 servings, p=0.02).

Practitioners should address food security to improve vegetable intake among Latina women.

Women with nutrition insecurity consumed fewer servings of vegetables compared to participants with nutrition security (1.7 vs. 2.5 servings, p=0.01).

Practitioners should focus on improving nutrition security to enhance vegetable intake.

Adherence to vegan and WFPB diets for ≥2 years is associated with lower BMI compared to <2 years.

Long-term adherence to vegan and WFPB diets may enhance weight loss outcomes.

MR-O and Conv-O similarly increased fecal fat percentage from 3.8% to 13.5%, confirming pharmacodynamic equivalence.

Both formulations can be considered equally effective in increasing fecal fat excretion.

The new weight loss product MR-OA retains the dietary energy loss pathway used in Conv-O.

MR-OA can be expected to function similarly to Conv-O in promoting fat loss.

Recent studies highlight the efficacy of diabetic agents and other novel therapies in shaping obesity-associated hypertension management guidelines.

Healthcare providers should consider incorporating diabetic agents and novel therapies into treatment plans.

Endobariatrics (EBT) offers durable weight loss with low complication rates.

EBT can be considered a viable option for patients seeking weight loss with minimal risks.

Obesity is associated with many health risks, including hypertension, hyperlipidemia, T2D, CHD, stroke, gallbladder disease, osteoarthritis, sleep apnea, respiratory problems, and some cancers.

Healthcare practitioners should be aware of the extensive health risks associated with obesity.

52.9% of Semaglutide users reached the 2.4 mg dose compared to 77.6% of Tirzepatide users reaching 15 mg.

Practitioners should note the higher success rate of Tirzepatide in reaching the maintenance dose.

Non-optimized dosing was associated with higher estimated monthly plan costs.

Practitioners should consider the cost implications of dosing strategies.

Management of weight should be patient-centered and consider age, health conditions, medications, and reproductive potential.

Practitioners should tailor weight management strategies to individual patient needs and circumstances.

Key considerations when treating weight in women include the impact on sex-specific conditions and reproductive considerations of anti-obesity medications.

Practitioners should incorporate sex-specific and reproductive considerations into weight treatment plans.

Discontinuation of obesity medications often results in weight regain and reversal of health benefits.

Practitioners should monitor patients for weight regain after discontinuation and implement strategies to mitigate this.

Treatment would produce 75,800 quality-adjusted life-years valued at $7 billion.

Obesity treatment can significantly enhance life quality and longevity for Medicaid beneficiaries.

82.7% of participants received no further prescriptions for antiobesity medications (AOMs) after their initial prescription.

This indicates a potential gap in ongoing obesity management for these patients.

The overall certainty of evidence for the effects of tirzepatide on physical function was rated as moderate due to risk of bias and inconsistency across studies.

Practitioners should be aware of the moderate certainty of evidence when considering tirzepatide for improving physical function.

Global Guidelines for obesity management emphasize the incorporation of novel therapies and integration of standards of care with up-to-date evidence.

Clinicians should adopt these guidelines to improve obesity management globally.

GLP-1-Rezeptoragonisten sollten als Krankenkassenleistung angeboten werden.

Praktiker sollten die Möglichkeit in Betracht ziehen, GLP-1-Rezeptoragonisten in die Krankenkassenleistungen aufzunehmen.

Among 7,493 members, rates of persistence and adherence to treatment were 60.8% and 60.1%, respectively.

Practitioners should note that adherence to GLP-1 therapies is moderate in this population.

Member-specific factors associated with lower rates of persistence and adherence included male sex, age (<40 years), diabetes, and a lack of weight-related comorbidities.

Understanding these factors can help tailor interventions to improve adherence.

Both groups achieved comparable reductions in body weight after 12 weeks.

Weight loss can be achieved with both dietary interventions during Tirzepatide therapy.

Preliminary dose-dependent weight reductions were observed with KN069.

KN069 may help in achieving weight loss in this demographic.

Surgeons should recognize GLP-1 RAs as complementary tools within multidisciplinary obesity and metabolic care pathways.

Surgeons should integrate GLP-1 RAs into their treatment strategies for obesity management.